Induction of γδ T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo

marrow complete remission (CR), and standard non-Hodgkin lymphoma (NHL) doses of rituximab in untreated CLL patients 4 cleared the bone marrow in only 9% of patients.We, therefore, would offer an alternative focus for future investigation with rituximab.Specifically, efforts should be focused on understanding potential factors such as stromal cell interaction that disrupt apoptosis, 5 CLL cell density, antibody penetration, and decreased access to complement and effector cells within the bone marrow that might prevent efficient clearance of tumor cells in the majority of patients.Such studies will facilitate development of alternative combination strategies to improve bone marrow responses with this promising combination therapy.